2015
Clinical characteristics and survival outcomes in BRCA1 -methylated epithelial ovarian cancer (Bmeth-OC): A pooled analysis of data for 1,278 patients across five studies.
Kalachand R, Ruscito I, Dimitrova D, Benedetti Panici P, Sehouli J, Olek S, Braicu E, Lu L, Katsaros D, Yu H, Carey M, Broaddus R, Lu K, Mills G, Harrell M, Agnew K, Swisher E, Grogan W, Stordal B, Hennessy B. Clinical characteristics and survival outcomes in BRCA1 -methylated epithelial ovarian cancer (Bmeth-OC): A pooled analysis of data for 1,278 patients across five studies. Journal Of Clinical Oncology 2015, 33: 5526-5526. DOI: 10.1200/jco.2015.33.15_suppl.5526.Peer-Reviewed Original Research
2014
The KRAS-Variant and miRNA Expression in RTOG Endometrial Cancer Clinical Trials 9708 and 9905
Lee LJ, Ratner E, Uduman M, Winter K, Boeke M, Greven KM, King S, Burke TW, Underhill K, Kim H, Boulware RJ, Yu H, Parkash V, Lu L, Gaffney D, Dicker AP, Weidhaas J. The KRAS-Variant and miRNA Expression in RTOG Endometrial Cancer Clinical Trials 9708 and 9905. PLOS ONE 2014, 9: e94167. PMID: 24732316, PMCID: PMC3986055, DOI: 10.1371/journal.pone.0094167.Peer-Reviewed Original ResearchConceptsEndometrial cancer riskType 2 endometrial cancerEndometrial cancerKRAS-variantCancer riskLymphovascular invasionSurvival outcomesTumor biologyType 1 endometrial cancerEndometrial cancer trialsOverall survival rateMiRNA expressionAge-matched controlsCase-control analysisFunctional germline variantsClinical characteristicsPatient ageTumor characteristicsCancer trialsTumor specimensSurvival rateType 1Germline variantsMiRNA expression levelsCancer
2012
Functional study of risk loci of stem cell-associated gene lin-28B and associations with disease survival outcomes in epithelial ovarian cancer
Lu L, Katsaros D, Mayne ST, Risch HA, Benedetto C, Canuto EM, Yu H. Functional study of risk loci of stem cell-associated gene lin-28B and associations with disease survival outcomes in epithelial ovarian cancer. Carcinogenesis 2012, 33: 2119-2125. PMID: 22822098, DOI: 10.1093/carcin/bgs243.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overCarcinoma, Ovarian EpithelialCircular DichroismCohort StudiesFemaleFollow-Up StudiesHumansMiddle AgedNeoplasm StagingNeoplasms, Glandular and EpithelialNeoplastic Stem CellsNucleic Acid ConformationOvarian NeoplasmsPolymorphism, Single NucleotidePrognosisPromoter Regions, GeneticQuantitative Trait LociReal-Time Polymerase Chain ReactionReverse Transcriptase Polymerase Chain ReactionRisk FactorsRNA, MessengerRNA-Binding ProteinsSurvival RateConceptsSingle nucleotide polymorphismsOvarian cancerEpithelial ovarian cancer survivalCancer-related risk factorsEpithelial ovarian cancerOvarian cancer survivalOvarian cancer prognosisHigher mortality riskCell-associated markersPrimary EOC tissuesLin-28BStem cell-associated markersAssociation of genotypesDominant modelPatient survivalSurvival outcomesBorderline significanceEOC tissuesCancer survivalRisk factorsReal-time PCRMortality riskCancer prognosisMultivariate analysisPotential biomarkers
2011
Physical activity and breast cancer survival: an epigenetic link through reduced methylation of a tumor suppressor gene L3MBTL1
Zeng H, Irwin ML, Lu L, Risch H, Mayne S, Mu L, Deng Q, Scarampi L, Mitidieri M, Katsaros D, Yu H. Physical activity and breast cancer survival: an epigenetic link through reduced methylation of a tumor suppressor gene L3MBTL1. Breast Cancer Research And Treatment 2011, 133: 127-135. PMID: 21837478, DOI: 10.1007/s10549-011-1716-7.Peer-Reviewed Original ResearchMeSH KeywordsBreast NeoplasmsCarcinoma, Ductal, BreastCarcinoma, LobularChromosomal Proteins, Non-HistoneDNA MethylationEpigenesis, GeneticFemaleGene ExpressionGene Expression ProfilingGene Expression Regulation, NeoplasticGenes, Tumor SuppressorHumansKaplan-Meier EstimateMotor ActivityRepressor ProteinsTumor Suppressor ProteinsConceptsBreast cancer patientsBreast cancer survivalCancer patientsPhysical activityOverall survivalSurvival outcomesTumor suppressor geneCancer survivalHormone receptor-positive tumorsModerate-intensity aerobic exerciseHigh expressionBreast cancer deathsReceptor-positive tumorsRandomized clinical trialsExercise-related changesSuppressor genePeripheral blood leukocytesBreast cancer diagnosisGene expressionDisease recurrenceAerobic exerciseCancer deathClinical trialsTumor featuresBlood leukocytesMicroRNA let-7a: A potential marker for selection of paclitaxel in ovarian cancer management
Lu L, Schwartz P, Scarampi L, Rutherford T, Canuto EM, Yu H, Katsaros D. MicroRNA let-7a: A potential marker for selection of paclitaxel in ovarian cancer management. Gynecologic Oncology 2011, 122: 366-371. PMID: 21571355, DOI: 10.1016/j.ygyno.2011.04.033.Peer-Reviewed Original ResearchConceptsLow let-7aDisease progressionLet-7aSurvival analysisEpithelial ovarian cancer patientsPlatinum-based chemotherapyOvarian cancer managementOvarian cancer patientsAddition of paclitaxelType of treatmentLet-7a expressionOvarian cancer resistanceOverall survivalDifferent chemotherapyEOC patientsPatient survivalSurvival outcomesDisease stageOvarian tumorsCancer patientsTumor gradeDisease outcomeCancer managementBetter survivalEOC survivalTelomerase expression and telomere length in breast cancer and their associations with adjuvant treatment and disease outcome
Lu L, Zhang C, Zhu G, Irwin M, Risch H, Menato G, Mitidieri M, Katsaros D, Yu H. Telomerase expression and telomere length in breast cancer and their associations with adjuvant treatment and disease outcome. Breast Cancer Research 2011, 13: r56. PMID: 21645396, PMCID: PMC3218945, DOI: 10.1186/bcr2893.Peer-Reviewed Original ResearchConceptsEndocrine therapyDisease outcomeAdjuvant treatmentTelomerase expressionBetter survival outcomesDisease-free survivalHormone receptor statusBreast cancer patientsRisk of deathTelomere lengthHigh telomeraseCause-specific mortalityBreast cancer prognosisBreast cancer cellsCancer cell resistanceHigh telomerase expressionOverall survivalPatient ageDisease recurrenceReceptor statusHistological typeAggressive diseaseSurvival outcomesDisease stageCancer patients
2008
TGF-β1 genotype and phenotype in breast cancer and their associations with IGFs and patient survival
Mu L, Katsaros D, Lu L, Preti M, Durando A, Arisio R, Yu H. TGF-β1 genotype and phenotype in breast cancer and their associations with IGFs and patient survival. British Journal Of Cancer 2008, 99: 1357-1363. PMID: 18827819, PMCID: PMC2570529, DOI: 10.1038/sj.bjc.6604689.Peer-Reviewed Original ResearchConceptsHigher TGF-β1TGF-β1 genotypesTGF-β1T genotypeHazard ratioBreast cancerBreast tumorsProportional hazards regression analysisLower TGF-β1Early-stage diseaseHazards regression analysisBreast cancer patientsLate-stage diseaseShorter overall survivalFresh tumor samplesTGF-β1 concentrationsBreast cancer progressionClinical characteristicsIGFBP-3Overall survivalDisease recurrenceReceptor statusPatient survivalSurvival outcomesDisease stage